Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Significant Decline in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 995,395 shares, a decline of 23.9% from the February 26th total of 1,307,493 shares. Currently, 3.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,654,814 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Liminatus Pharma has a consensus rating of “Sell”.

Liminatus Pharma Price Performance

Shares of LIMN traded down $0.01 during mid-day trading on Tuesday, reaching $0.17. 1,711,803 shares of the company’s stock traded hands, compared to its average volume of 1,549,055. The stock’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.88. Liminatus Pharma has a 12 month low of $0.17 and a 12 month high of $33.66. The stock has a market cap of $5.34 million and a P/E ratio of -1.43.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.34) earnings per share (EPS) for the quarter.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.